Sivik Global Healthcare LLC Sells 1,000 Shares of Cencora, Inc. (NYSE:COR)

Sivik Global Healthcare LLC reduced its stake in shares of Cencora, Inc. (NYSE:COR) by 3.8% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 25,000 shares of the company’s stock after selling 1,000 shares during the period. Cencora makes up approximately 2.4% of Sivik Global Healthcare LLC’s holdings, making the stock its 18th biggest holding. Sivik Global Healthcare LLC’s holdings in Cencora were worth $5,627,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of COR. New Millennium Group LLC acquired a new position in shares of Cencora in the second quarter valued at about $26,000. TCTC Holdings LLC bought a new position in Cencora during the 1st quarter worth $29,000. TFO Wealth Partners LLC acquired a new stake in Cencora during the 1st quarter valued at approximately $30,000. MFA Wealth Advisors LLC bought a new position in shares of Cencora in the 2nd quarter worth about $30,000. Finally, Concord Wealth Partners acquired a new stake in Cencora in the third quarter worth $30,000. Institutional investors own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Wells Fargo & Company raised their target price on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. Leerink Partners lowered their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. Robert W. Baird upped their price target on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. UBS Group lifted their price objective on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, Barclays lifted their price objective on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $271.20.

Insider Buying and Selling at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 15.80% of the stock is owned by insiders.

Cencora Price Performance

Shares of COR stock traded down $2.24 during mid-day trading on Thursday, hitting $247.73. 47,972 shares of the stock were exchanged, compared to its average volume of 1,401,661. The company has a market cap of $48.82 billion, a PE ratio of 33.28, a price-to-earnings-growth ratio of 1.66 and a beta of 0.44. Cencora, Inc. has a 52-week low of $191.11 and a 52-week high of $251.56. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The firm has a fifty day moving average of $232.38 and a 200 day moving average of $231.00.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.55 per share. This is a positive change from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend is Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.89%. Cencora’s dividend payout ratio is presently 27.16%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.